Arcadia Biosciences(US:RKDA)2025-05-08 12:05Financial Performance - Total revenues for Q1 2025 were $1,200,000, an increase of 21.5% compared to $987,000 in Q1 2024[4] - Net income attributable to common stockholders for Q1 2025 was $2,599,000, compared to a net loss of $2,423,000 in Q1 2024[4] - Basic net income per share from continuing operations was $1.90 in Q1 2025, a significant improvement from a loss of $0.70 in Q1 2024[4] - Operating expenses for Q1 2025 were $670,000, a decrease of 74% from $2,575,000 in Q1 2024[4] - The company reported a gain on the sale of intangible assets of $750,000 in Q1 2025[4] Assets and Liabilities - Total current assets decreased to $8,846,000 as of March 31, 2025, down from $9,242,000 as of December 31, 2024[2] - Total liabilities decreased to $4,085,000 as of March 31, 2025, compared to $7,294,000 as of December 31, 2024[2] Cash Flow - Cash and cash equivalents at the end of Q1 2025 were $3,159,000, down from $4,242,000 at the beginning of the period[5] - The company experienced a net cash used in operating activities of $1,588,000 in Q1 2025, an improvement from $3,210,000 in Q1 2024[6] Research and Development - Research and development expenses were $0 in Q1 2025, down from $6,000 in Q1 2024[4]